Remicade use extended

The licence for Remicade (infliximab) has been extended to include the treatment of Crohn's disease in paediatrics.

Remicade may be used in children aged six to 17 years unresponsive or intolerant to corticosteroid, immunosuppressant and primary nutrition therapy.

Further information: Schering-Plough 01707 363636

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.

Researchers query safety of delaying antibiotics for UTI in elderly

Researchers query safety of delaying antibiotics for UTI in elderly

Delaying or withholding antibiotics for symptoms of...

Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.